Osimertinib was associated with a 2.2-fold higher rate of heart failure, a 2.1-fold higher rate of atrial fibrillation, and a 6.6-fold higher rate of QT prolongation compared with other EGFR inhibitors for NSCLC (Anand et al., 2019). This evidence concerns the gene EGFR and non-small cell lung carcinoma.